HLA Loci and Recurrence of Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplantation

Brian I. Shaw, MD,1 Alejandro Ochoa, PhD,2 Cliburn Chan, MD,2 Chloe Nobuhara, BS,3 Rasheed Gbadegesin, MD,4 Annette M. Jackson, PhD,1,5 and Eileen T. Chambers, MD1,4

Background. Recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation accounts for the majority of allograft failures in children with primary FSGS. Although current research focuses on FSGS pathophysiology, a common etiology and mechanisms of disease recurrence remain elusive. Methods. We performed a retrospective review of the Scientific Registry of Transplant Recipients to determine the association of specific HLA recurrence of FSGS. Kidney transplant recipients under the age of 19 who were diagnosed with FSGS, who were transplanted after January 1, 2000, and who had complete HLA data were included in the study. We performed simple logistic regression on all HLA A, B, C, DR, and DQ represented in the dataset and FSGS recurrence and then determined those associated with recurrence using the Benjamini–Hochberg method for multiple comparisons. For those HLAs that were associated with recurrence, we further determined the effect of matching recipient and donor HLA with recurrence. Results. HLA DR7, DR53, DQ2, DR52, and DQ7 were associated with increased or decreased risk of recurrent disease after transplantation. We identified a risk haplotype consisting of HLA-DR7, DR53, and DQ2 that was consistently associated with an increased risk of recurrence (odds ratio 1.91; 95% confidence interval, 1.44-2.54, \( P < 0.001 \)). We also found that donor/recipient concordance for HLA-DQ7 was associated with a decreased risk of recurrence (odds ratio 0.42; 95% confidence interval, 0.37-0.53, \( P = 0.009 \)). Conclusions. HLA profiles may be used for risk stratification of recurrence of FSGS in pediatric kidney transplant recipients and deserves further study.

(Transplantation Direct 2021;00: e00; doi: 10.1097/TXD.0000000000001201. Published online 26 August, 2021.)
class II alleles and recurrence of primary NS, it is plausible that specific HLA may also confer risk of disease recurrence following kidney transplantation.15-24 and represent an opportunity to predict posttransplant FSGS risk.

In this analysis, we sought to determine if specific HLAs were associated with posttransplant FSGS recurrence in pediatric recipients. We first identified recipient HLA associated with primary FSGS and then explored the relationship of recipient and donor HLA with FSGS recurrence posttransplant.

**MATERIALS AND METHODS**

**Data Source and Study Population**

We used data from the Scientific Registry of Transplant Recipients (SRTR). This study was IRB approved and determined exempt (Pro00106450). The SRTR data system includes data on all donors, waitlisted candidates, and transplant recipients in the United States. These data are submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration, US Department of Health and Human Services provides oversight to the activities of the Organ Procurement and Transplantation Network and SRTR contractors. To enrich our cohort for patients with primary NS, we examined the recurrence rate of patients whose primary indication for transplantation was focal glomerulosclerosis or FSGS and included only pediatric patients (age <18 y). We excluded those with potential secondary causes of FSGS, such as diabetes, congenital anomalies of kidney and urinary tract, and other glomerulonephritides.

Therefore, all patients who underwent kidney transplant after 1999 (334,947), who were listed by age 18 (15,510), who did not have diabetes (15,344), who were diagnosed with focal glomerulosclerosis or FSGS (1906), who underwent kidney alone transplant (1901), who were in the follow-up dataset (txf_ki, 1800), who were undergoing their first transplant (1718), who had data on recurrence (1530) with at least 6 mo of follow-up (1512), and who had complete recipient HLA-DR and HLA-DQ information (final N = 1196) were included in this analysis (Figure 1).

**Primary and Secondary Outcomes**

Our primary outcome was recurrence of their primary disease (FSGS) as reported by the individual transplant centers. Secondary outcomes examined graft and patient survival time and time to disease recurrence.

**Statistical Analyses**

Patient and donor characteristics were summarized and compared using chi-squared test for categorical variables and Wilcoxon Rank-Sum tests for continuous variables as appropriate using 2-tailed P values. Of note, a single donor could contribute 2 kidneys, and therefore, the number of donors and recipients are not exactly equal. Univariable logistic regression was performed to determine the association of an HLA antigen (A, B, C, DR51, DR52, DR53, DR, and DQ) with disease recurrence using likelihood ratio tests and 2-tailed P values. Of note, generally only serological typing is reported to UNOS. When molecular data were available, they were converted to serologic types for consistency.25 For all recipient HLA loci except HLA-C, complete serologic data were available for all HLA types. As the association of class I HLA was an exploratory analysis, we performed a complete case analysis for HLA-C associations.

![Figure 1](https://example.com/figure1.png)

**FIGURE 1.** Cohort definition flow diagram. FSGS, focal segmental glomerulosclerosis.

After serial univariable logistic regression across all HLA antigens in the dataset, we tested for significance using the Benjamini–Hochberg method with a false discovery rate of 20%. For all HLA that were significantly correlated at this
point, we performed a second set of logistic regression analyses in which we examined the dose effect (ie, being a heterozygote or homozygote for each HLA) of these HLA in the recipient and the risk of recurrence as well as the dose effect of the donor having a concordant HLA with the recipient. We performed a complete case analysis for both of these dose effect scenarios for each HLA (ie, we excluded recipients from the concordance analysis if their donor lacked HLA information).

We performed multiple regression to determine our ability to predict posttransplant recurrence. We performed model construction using factors previously postulated to increase the risk of NS recurrence after transplant (age of disease onset, living donor type, race, and ethnicity) as well as all HLA antigen level data (recipient, donor, and concordant) that were significantly correlated with recurrence. We assessed for collinearity by using correlation matrices and evaluation of the variance inflation factor. We chose our final model by examining the Akaike information coefficient, Bayesian information coefficient, and by examining likelihood ratio tests between models as less significant terms were removed. Receiver operating characteristic for the final models were calculated.

We also performed a time to event analysis for time to recurrence using the Kaplan–Meier method to plot curves and the Log-rank test to compare them.

A sensitivity analysis repeating the initial step of this analysis—performing simple logistic regression to determine the association between recurrence and HLA antigen—was repeated accounting for race (White versus non-White) and Latino ethnicity did not substantively change results. All analyses were performed using STATA v. 15 (Statacorp, College Station, TX).

RESULTS

Cohort Characteristics and Graft Failure Associated With FSGS Recurrence

Patient and donor characteristics are summarized in Tables 1 and 2, respectively. Our cohort consisted of 1196 patients. In the cohort as a whole, the median age at listing was 15 (interquartile range [IQR] 11–17), 43% were female, 58% were white, 36% were Black, 27% were Latino, and the median BMI was 20 (IQR 17–24). Overall, 28% of patients in our cohort experienced recurrence. Patients with posttransplant FSGS recurrence were younger (median [Med] age 14 [IQR] [10–17] versus 16 [12–18]), and had lower albumin (Med [IQR] 3.3 [2.4–3.8] versus 3.7 [3.2–4.2]) and body mass index (Med [IQR] 19.1 [17.0–23.0] versus 20.5 [17.5–24.8]). Additionally, recurrence was associated with earlier time to graft failure, with median death censored graft survival of 5.4 years in patients with recurrence compared to 13.1 years in patients without recurrence (Figure 2, Log-rank $P < 0.001$).

Recurrence of FSGS After Transplant Is Predicted by Recipient HLA

We examined the association of HLA antigens with recurrence at any time posttransplant. In Figure 3A, we see that HLA antigens HLA-B13, DR7, DQ2, and DR53 were most highly associated with recurrence risk, whereas HLA-C3, B58, DR52, DQ6, and DQ7 were associated with decreased rates of recurrence when controlling for a false discovery rate of 20%. Of note, we retained HLA-B13, DR7, DR52, and DR53 with a false discovery rate of 5%. We also investigated alleles associated with early recurrence (reported within the first year posttransplant) with a false discovery rate of 5% and obtained positive associations with B13, DR7, DR53, DQ2, and DQ8, and negative associations with DR52 and DQ6.

### TABLE 1.

Recipient characteristics

|                          | No recurrence N = 862 | Recurrence N = 334 | $P$  |
|--------------------------|-----------------------|--------------------|------|
| Gender (female), n (%)    | 371 (43%)             | 146 (44%)          | 0.83 |
| Age at transplant, Med (IQR) | 16.0 (12.0–18.0)      | 14.0 (10.0–17.0)   | <0.001|
| Age at listing, Med (IQR) | 15 (12–17)            | 13 (9–16)          | <0.001|
| Race, n (%)              |                       |                    | 0.20 |
| Asian                    | 27 (3%)               | 5 (1%)             |      |
| Black                    | 323 (37%)             | 115 (34%)          |      |
| Multiracial              | 11 (1%)               | 6 (2%)             |      |
| Native American          | 5 (1%)                | 1 (0%)             |      |
| Pacific Islander         | 3 (0%)                | 4 (1%)             |      |
| White                    | 493 (57%)             | 203 (61%)          |      |
| Ethnicity (Latino), n (%)| 251 (29%)             | 79 (24%)           | 0.058|
| Time on dialysis (mo), Med (IQR) | 15 (7–27)          | 16 (8–29)          | 0.42 |
| Albumin (g/dL), Med (IQR) | 3.7 (3.2–4.2)         | 3.3 (2.4–3.8)      | <0.001|
| Body mass index, Med (IQR) | 20.5 (17.5–24.8)      | 19.3 (17.0–23.0)   | 0.002|

Bolded $P$ are significant at $P < 0.05$ level. $^a$0%–5% Missing. $^b$5%–10% Missing. $^c$10%–20% Missing. $^d$>20% Missing. IQR, interquartile range; Med, median.
All alleles except DQ8 were noted in our initial analysis. We next assessed a dose effect of certain antigens by determining the odds of recurrence given recipient heterozygosity or homozygosity (Figure 3B). In general, antigens showed a dose-response pattern, with homozygosity causing the point estimate to be more extreme in the same direction as the heterozygote, though this trend was not observed for DQ7. Note that B13, B58, DR52, and DR53 are excluded from this analysis either due to lack of data on heterozygosity or insufficient number of heterozygotes for analysis. Since homozygotes are less common than heterozygotes, there is less power to detect differences in association between those 2 dosages.

Defining a Recipient HLA Risk Haplotype for FSGS Recurrence

Given that HLA-DR7, DR53, and DQ2 represent a common HLA haplotype and because we noted that these antigens were positively correlated with one another (Figure 4), we interrogated the association of this potential multi-HLA antigen recipient haplotype (now referred to as the risk haplotype) with recurrence. In a simple logistic regression analysis, the risk haplotype increased the risk of recurrence nearly 2-fold (odds ratio [OR] 1.91 95% confidence interval [CI] 1.44-2.54, \( P < 0.001 \)). The risk haplotype also is associated with increased risk of early recurrence within the first year (OR 2.27; 95% CI 1.65-3.13). Expressed as raw percentages, 27% of those with the risk haplotype recurred within the first year, whereas among patients with the C3 allele, only 6% recurred in the same time period.

Recipient HLA Antigens Are Associated With Time to FSGS Recurrence

We assessed whether our identified recipient HLA antigens were associated not only with a binary event of recurrence but...
also time to recurrence. Kaplan–Meier plots for each associated HLA antigen are shown in Figure 5. Overall, the results are similar to those shown in Figure 2, with a decrease in recurrence-free survival for the risk haplotype and B13 and an increase in recurrence-free survival for HLA-B58, C3, DR52, DQ6, and DQ7.

**Impact of Donor HLA on FSGS Recurrence**

We also investigated a role for donor HLA in disease recurrence and potential dose effects when the donor shared a risk or protective HLA antigen with the recipient. The donor HLA alone did not appear to impact recurrence rate (data not shown); however, there was an apparent dose effect for recipient/donor pairs that shared DQ7. The proportion of patients that recurred was lower in recipient/donor pairs that shared the protective HLA-DQ7 antigen (13.3% for concordance versus 23.3% for the recipient allele alone). This effect was confirmed when performing multiple logistic regression using an interaction term between donor and recipient antigens (OR 0.42; 95% CI 0.37-0.53, P = 0.009). Under logistic regression, no other HLA antigens were observed to impact recurrence when shared between recipient and donor.

**Using HLA Allows for the Modest Overall Prediction of FSGS Recurrence**

We next constructed a multivariable model for the prediction of disease recurrence (Table 3). Our initial model included
**TABLE 3.**

Multivariable models for the prediction of FSGS recurrence

| Term                  | Initial model OR (95% CI) | Final model OR (95% CI) |
|-----------------------|---------------------------|-------------------------|
| Race (Black = 1)      | 0.933 (0.873, 0.993)      | 0.931 (0.871, 1.000)    |
| Ethnicity (Latino = 1)| 0.648* (0.653, 0.664)     | 0.653* (0.662, 0.664)   |
| Recipient risk haplotype | 0.444, 0.944 (0.451, 0.948) | 1.560* (1.718**) |
| Recipient DR52        | 1.108, 2.224 (1.231, 2.397) | 1.108, 2.224 (1.231, 2.397) |
| Recipient B13         | 0.802                     | 0.802                   |
| Recipient C3          | 0.713, 3.040 (0.636, 1.359) | 0.270** (0.270**)       |
| Recipient B58         | 0.112, 0.652 (0.112, 0.652) | 0.112, 0.650 (0.112, 0.650) |
| Recipient DQ7         | 0.283, 1.072 (0.265, 0.996) | 0.93 (0.636, 1.359)     |
| DQ7 match             | 0.361** (0.334**, 0.964    |
| Age at listing        | 0.195, 0.670 (0.193, 0.577) | 0.932** (0.931**) |
| Related donor         | 0.901, 0.965 (0.900, 0.964) | 1.258                   |
| Constant              | 0.856, 1.828 (1.482)       |

Boldered P values are significant. 
*P < 0.05
**P < 0.01
***P < 0.001.

CI, confidence interval; FSGS, focal segmental glomerulosclerosis; OR, odds ratio.

all terms previously seen to be significant on univariable analysis including recipient HLA (the risk haplotype [HLA-DR7-DR53-DQ2], HLA-B13, DR52, C3, B58, DQ6, and DQ7), recipient/donor sharing of HLA-DQ7, as well as age at listing, and living-related donor status. To account for population structure, we also included non-White race and Latino ethnicity as fixed terms that would not be removed from the model. The initial model was moderately predictive of recurrence (c-statistic 0.68, 95% CI 0.64-0.72). However, our final model was as predictive (c-statistics 0.68, 95% CI 0.64-0.71) but had an improved Akaike information coefficient (1098 versus 1102) and Bayesian information coefficient (1142 vs. 1166). The final model included the recipient risk haplotype, B58, C3, DQ6, concordance at DQ7, and age at listing as explanatory variables.

**DISCUSSION**

This study represents the first analysis of HLA and FSGS disease recurrence following transplantation in pediatric patients. We demonstrate that certain HLA types are associated with either an increased or decreased risk of recurrence and identify an HLA risk haplotype that encompasses previously defined HLA antigens from NS genome-wide association study analyses. Finally, we show that concordance between donor and recipient HLA may additionally modify recurrence risk.

Multiple teams have sought to better understand the underlying pathophysiology of idiopathic NS and specifically FSGS. FSGS is defined on biopsy as segmental destruction of the glomerular capillaries and foot process effacement, providing insight into the structural changes that lead to loss of nephron function. However, full understanding of the environmental, immunologic, and/or genetic triggers that contribute to these destructive changes remains elusive. Familial clustering of FSGS spurred gene discovery studies that revealed a large number of pathogenic gene variants that cause monogenic FSGS; however, these only account for approximately 30% of steroid-resistant nephrotic syndrome/FSGS cases.27,28 The majority of genes identified encode for proteins essential to the integrity29 and function of the glomerular podocyte.30 In contrast, the use of immunosuppressive agents has been shown to slow or mitigate disease progression in numerous cases of FSGS, suggesting an underlying immunological process for many patients.31-37 Experimental and clinical data show improvement of proteinuria after treatment with plasmapheresis, which supports the hypothesis that a circulating factor contributes to podocyte injury.38 Multiple candidate factors have been identified in blood including urokinase-type plasminogen activator receptor, cardiocrin-like cytokine factor-1, anti-CD40 antibodies, and apolipoprotein A-Ib.39-43

HLA disease associations have been documented across numerous primary kidney disorders suggesting an early immunologic etiology for many patients evaluated for transplantation. Indeed, the 3 HLA identified in our risk haplotype—HLA DR7, DR53, and DQ2—have been previously identified in multiple studies of primary NS.15-18,20,24 Additionally, all 3 of these HLA and the risk haplotypes were associated with early recurrence, which is likely of more clinical concern than later recurrence. This may not be surprising given the central role of HLA molecules in initiating adaptive immune responses and their implication in many destructive autoimmune processes. There is evidence that class II HLA polymorphisms have evolved to offer maximal protection from pathogens at the expense of potential self-reactivity.44 In the present study, 4 HLA were associated with increased risk of recurrent FSGS, with 3 being class II HLA, consistent with this theory. Our data, which utilize direct HLA typing (either serological typing or serological equivalents of molecular typing) and not single nucleotide polymorphism imputation extend the results of previous GWAS20,21,24 in a diverse cohort. This is important, as previous examination of single nucleotide polymorphism imputation of HLA has found errors, especially in non-White populations.45 Though there have been some small historical studies examining the relationship of serologic HLA type with primary NS and FSGS,46,47 we are the first to examine the association of HLA antigens in posttransplant FSGS recurrence.

One unique finding of this study is that HLA concordance between the recipient and kidney donor appeared to influence the FSGS recurrence risk. Whereas the conferment of risk was mediated only by the recipient HLA, the protective effect of HLA DQ7—associated with a decreased risk of recurrence—was determined by concordance with the donor. Though the mechanism by which concordance causes protection is unclear, it is possible that HLA DQ7 molecules are less likely to present peptides, which license immunologically mediated destruction leading to changes consistent with FSGS. Additionally, it is unclear if our inability to find this concordance effect more broadly is due to a true biological difference or mediation at the allelic and not the antigen level. Given that there are conflicting studies on the effect of donor factors in the risk of recurrence,20-23 further studies that specifically
define HLA alleles based on their genetic sequence would be helpful in answering the clinical question of whether or not HLA concordance—of an allele or haplotype—leads to modifications in the risk of recurrent NS and FSGS.

More mechanistically intuitive is the fact that multiple class II HLA are associated with an increased risk of recurrence. HLA class II expression in the kidney is constitutively low, but is upregulated in response to inflammation and injury. Therefore, interaction between HLA class II and adaptive immunity generally involves the presentation of peptides in a proinflammatory environment. Indeed, studies to determine the expression of class II HLA in the kidneys of patients with FSGS may yield insights into the pathogenesis of the disease and the potential for recurrence. Although our findings are important, our study has limitations. First, the data are retrospective from a large national registry. Reporting of the clinical event of recurrent FSGS may be incomplete; however, the generally high percentage of patients experiencing recurrence (28%) is compatible with known rates in the literature and not compatible with monogenic FSGS, which has a much lower recurrence rate.4,14,15 Also, all included patients are pediatric and do not have diabetes, limiting the chance of patients with secondary FSGS being included in our cohort. Our dataset does not contain diagnosis codes for other forms of NS such as minimal change disease; therefore, we may be excluding some patients inappropriately. The dataset also does not contain information regarding patient histology, known to be important in the clinical course of FSGS. Most importantly, the HLA data are reported from a wide variety of centers and are at the antigen level, whereas most genetic studies have found associations of HLA and FSGS at the allele level.21 This limitation may be a reason that we did not detect associations between all previously identified HLA and recurrent FSGS. However, our identification of a common risk haplotype DR7-DR53-DQ2 adds credibility to the associations we did find. Finally, it is possible that the associations we see here implicate not HLA in the pathogenesis of FSGS but rather other variants in linkage disequilibrium with those HLA.

In conclusion, we find that certain recipient HLAs are associated with risk of recurrent FSGS in pediatric kidney transplant recipients. Further prospective studies should be undertaken to validate these HLA as risk factors to further our understanding of the pathogenesis of FSGS and disease recurrence as well as to improve donor selection, and perioperative management for pediatric patients with FSGS.

ACKNOWLEDGMENTS

The data reported here have been supplied by the Hennepin Healthcare Research Institute as the contractor for the SRTR. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the US Government. We would like to acknowledge our funding from the National Institutes of Allergy and Infectious Disease (U01 AI112385-01) and the National Heart Blood and Lung Institute (R38HL143612-03).

REFERENCES

1. Fine RN. Recurrence of nephrotic syndrome/local segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol. 2007;22:496–502.

2. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol. 1992;2:S258–S263.

3. Kim EM, Striegel J, Kim Y, et al. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int. 1994;45:1440–1445.

4. Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int. 2001;59:328–333.

5. Hanhara S, Peddi VR, Savin VJ, et al. Recurrence and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry. Am J Kidney Dis. 1998;31:928–931.

6. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347:103–109.

7. Verghese PS, Rheault MN, Jackson S, et al. The effect of peri-transplant plasmapheresis in the prevention of recurrent FSGS. Pediatr Transplant. 2018;22:e13154.

8. Hsu Y, Driskill M, McCarthy H, et al. Treatment of recurrent focal segmental glomerulosclerosis post-kidney transplantation in Australia and New Zealand children: a retrospective cohort study. Pediatr Transplant. 2018;22:e13185.

9. Gonzalez E, Ettenger R, Rianthavorn P, et al. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant. 2011;15:495–501.

10. Teepe AM, Arika P, McCutcheon SJ. Long-term outcome of kidney transplantation in recipients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2016;11:2041–2046.

11. Ding WY, Koziell A, McCarthy HJ, et al. Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol. 2014;25:1342–1348.

12. Baum MA. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant. 2014;18:329–333.

13. Nehus EJ, Goebel JW, Superc P, et al. Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk. Transplantation. 2013;96:550–554.

14. Pelletier JH, Kumar KR, Engen R, et al. Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings. Pediatr Nephrol. 2018;33:1773–1780.

15. Konrad M, Mytilineos J, Boulouas F, et al. HLA class II associations with idiopathic nephrotic syndrome in children. Tissue Antigens. 1994;43:275–280.

16. Clark AG, Vaughan RW, Stephens HA, et al. Genes encoding the beta-chains of HLA-DR7 and HLA-DQw2 define major susceptibility determinants for idiopathic nephrotic syndrome. Clin Sci (Lond). 1990;78:391–397.

17. Kobayashi T, Ogawa T, Takahashi K, et al. HLA-DQB1 allele associates with idiopathic nephrotic syndrome in Japanese children. Acta Paediatr Jpn. 1995;37:293–296.

18. Abe KK, Michinaga I, Hiratsuka T, et al. Association of DQB1*0302 allotypes in Japanese pediatric patients with steroid-sensitive nephrotic syndrome. Nephron. 1995;70:28–34.

19. Kari JA, Sinnott P, Khan H, et al. Familial steroid-responsive nephrotic syndrome and HLA antigens in Bengali children. Pediatr Nephrol. 2001;16:346–349.

20. Gbadegesin RA, Adeyemo A, Webb NJ, et al; Mid-West Pediatric Nephrology Consortium. HLA-DQAI and PLCG2 are candidate risk loci for childhood-onset steroid-sensitive nephrotic syndrome. J Am Soc Nephrol. 2015;26:1701–1710.

21. Adeyemo A, Esezobor C, Solarin A, et al. HLA-DQA1 and APOL1 as risk loci for childhood-onset steroid-sensitive and steroid-resistant nephrotic syndrome. Am J Kidney Dis. 2016;71:409–406.

22. Debiec H, Dossier C, Letouzé E, et al. Transethnic, genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome. J Am Soc Nephrol. 2018;29:2000–2013.

23. Jia X, Horinouchi T, Hitomi Y, et al; Research Consortium on Genetics of Childhood Idiopathic Nephrotic Syndrome in Japan. Strong association of the HLA-DR-DQ locus with childhood steroid-sensitive nephrotic syndrome in the Japanese population. J Am Soc Nephrol. 2018;29:2189–2199.

24. Dufek S, Cheshire C, Levine AP, et al. Genetic identification of two novel loci associated with steroid-sensitive nephrotic syndrome. J Am Soc Nephrol. 2019;30:1375–1384.

25. Kaur N, Kranosdor EP, Pando MJ, et al. Mapping molecular HLA typing data to UNOS antigen equivalents. Hum Immunol. 2018;79:781–789.
26. National Marrow Donor Program. Haplostats application. 2015. Available at https://www.haplostats.org/haplostats?execution=e1s1. Accessed December 2020.

27. Sadowski CE, Lovric S, Ashraf S, et al; SRNS Study Group. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26:1279–1289.

28. Sampson MG, Gilles CE, Robertson CC, et al. Using population genetics to interrogate the monogenic nephrotic syndrome diagnosis in a case cohort. J Am Soc Nephrol. 2016;27:1970–1983.

29. Caridi G, Bertelli R, Carrea A, et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol. 2001;12:2742–2746.

30. Akilesh S, Suleiman H, Yu H, et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Am Soc Nephrol. 2001;12:2742–2746.

31. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7:56–63.

32. Montané B, Abitbol C, Chandar J, et al. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol. 2003;18:772–777.

33. Tumlin JA, Miller D, Near M, et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2006;1:109–116.

34. Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004;19:3062–3067.

35. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:281–287.

36. Geary DF, Farine M, Thorner P, et al. Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol. 1984;22:109–113.

37. Basu B, Mahapatra TK, Mondal N. Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics. 2015;136:e132–e139.

38. Vécsei AK, Müller T, Schratzberger EC, et al. Plasmapheresis-induced remission in otherwise therapy-resistant FSGS. Pediatr Nephrol. 2001;16:898–900.

39. Lopez-Hellin J, Cantarell C, Jimeno L, et al; GREAT Study Group. A form of apolipoprotein a-II is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant. 2013;13:493–500.

40. Savin VJ, Sharma M, Zhou J, et al. Multiple targets for novel therapy of FSGS associated with circulating permeability factor. Biomol Res Int. 2017;2017:6232616.

41. Sharma M, Zhou J, Gauchat JF, et al. Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiothrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res. 2015;166:384–398.

42. Wei C, Sigdel TK, Sarwal MM, et al. Circulating CD40 autoantibody and suPAR synergy drives glomerular injury. Ann Transl Med. 2015;3:300.

43. Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pre-transplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6:256ra136.

44. Mangalam AK, Taneja V, David CS. HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. J Immunol. 2013;190:513–518.

45. Pappas DJ, Lizee A, Paunic V, et al. Significant variation between SNP-based HLA imputations in diverse populations: the last mile is the hardest. Pharmacogenomics J. 2018;18:367–376.

46. Gerbase-DeLima M, Pereira-Santos A, Sesso R, et al. Idiopathic focal segmental glomerulosclerosis and HLA antigens. Braz J Med Biol Res. 1998;31:387–389.

47. Glicklich D, Haskell L, Senitzer D, et al. Possible genetic predisposition to idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis. 1988;12:26–30.

48. Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004;66:571–579.